UK markets close in 54 minutes

AB Science S.A. (0Q77.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
2.6250+0.0200 (+0.77%)
As of 08:10AM GMT. Market open.
Full screen
Loading interactive chart…
  • Globe Newswire

    AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

    PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT CHAIN, AN IMPORTANT BIOMARKER FOR NEURODEGENERATIVE DISORDERS Paris, March 13, 2024, 12.45pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of new preclinical results for masitinib in neurodegenerative diseases (NDD). Findings have been published on the

  • GlobeNewswire

    AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

    PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT Paris, March 7, 2024, 3pm CET AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development. The webcast presentation is available on the company’s website, in the section « Press Releases »: https://www.ab-science.com/news-and-media/press-releases/ The presentation covered four topics: Status of condi

  • Globe Newswire

    AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company

    PRESS RELEASE TWO NEW FINANCIAL ANALYSIS FIRMS INITIATE COVERAGE OF AB SCIENCE Paris, March 6, 2024, 8.15pm CET AB Science SA (Euronext - FR0010557264 - AB) announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated the coverage of the Company. DNA Finance estimates that AB Science stands out as a compelling investment opportunity in the biotech sector. In Extenso has initiated a strong buy opinion on the share. These new coverages aim to strengthen the AB Sc